Regeneron Q2 revenue surges 163% to $5.14B

Thursday, 05. August 2021 12:38

Regeneron Pharmaceuticals reported on Thursday the company's revenue in the second quarter of 2021 surged 163% to $5.14 billion, significantly outperforming the figure estimated by analysts on the back of strong sales of its COVID-19 antibody cocktail, Regen-Cov.

Sales of the experimental antibody combination, which received emergency use authorization from the US Food and Drug Administration in November 2020, reached $2.76 billion, according to the update from Regeneron. Meanwhile, the drugmaker unveiled earnings per share in the same three-month period were $27.97 on net income of $3.1 billion.

"Regeneron had outstanding performance in the second quarter during which we delivered to the U.S. government the entire order for our COVID-19 antibody cocktail and recognized record global sales from our EYLEA and Dupixent franchises," President and CEO Leonard S. Schleifer said.

Shares of Regeneron jumped 1.86% to $591.77 in premarket trading.

Related Links: Regeneron Pharmaceuticals Inc.
Breaking the News / JC